Prima Biomed shares jumped more than 25% after European authorities endorsed the further development of a treatment for breast cancer.
The European Medicines Agency (EMA) confirmed its endorsement for a development program of Prima Biomed’s IMP321 treatment.
A planned study is now expected to start in Europe in the 4th quarter of 2015. This is a key step leading to marketing authorisation in the EU.
Frédéric Triebel, Prima’s chief scientific and medical officer, says the EMA’s scientific advice represents a “significant step forward”.